Navigation Links
Eurofins MWG Operon’s Express Oligos Provide Faster Than Ever Service
Date:2/6/2013

(PRWEB) February 06, 2013

Expanding on the mission to deliver ISO-quality research products and services ‘faster than ever,’ Eurofins MWG Operon announces their entry into the overnight oligonucleotide market. The new Express Oligo service can be ordered as late as 4:00 p.m. ET for delivery by 10:30 the next morning. As research projects often require oligo synthesis based on the latest experimental results, customers throughout the US can rely on Eurofins MWG Operon to accept orders an hour later than other oligo providers.

“With this new and very inexpensive service we further strengthen our position to be the fastest DNA Company in the US. We currently offer overnight DNA sequencing for all US locations and now the fastest oligo service in the industry for the US,” stated Martin Kunz, CEO of Eurofins MWG Operon Inc. “The new Express Oligo service benefits the research of any institution or company pursuing development in fast cycles, as we now offer primer synthesis and DNA sequencing - both in less than 24 hours and faster than any competitor.”

“Process improvements and optimized logistics make faster delivery possible and also ensure Express Oligos undergo the same ISO-certified quality tests as our standard oligos.” stated Dr. Philipp Wenter, VP Manufacturing of Eurofins MWG Operon Inc. “We provide a clear research advantage since we are the only manufacturer that does full QC on overnight oligos, including Mass-Spec, before shipment. All of our oligos are produced under ISO 9001/13485 specifications.”

Visit http://www.operon.com/express-oligo for more information about overnight oligo synthesis services.

About Eurofins MWG Operon
Eurofins MWG Operon, a member of the Eurofins Group with major offices and production facilities in the United States, Europe, and Asia, is an international provider of DNA sequencing services, DNA synthesis products, and bioinformatics services for academic and industrial research. The company’s strengths are its strong customer orientation, fast service, and high quality. For additional information, please visit our website at http://www.operon.com.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10400178.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Free Research Report on Dyax Corp., Ebix, Inc., 8x8, Inc., EnerSys and Express Scripts Holding Co.
2. transOMIC technologies Releases Tagged ORF Clones for Protein Expression
3. Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview
4. Exon skipping to restore gene expression is promising therapeutic strategy for muscular dystrophy
5. Genedata Expressionist® Established as Data Analysis Platform for Oncological Research
6. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
7. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
8. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
9. Veracyte Announces Medicare Coverage for Its Afirma® Gene Expression Classifier for Improved Thyroid Nodule Diagnosis
10. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
11. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 ReportsnReports.com adds 2016 ... its pharmaceuticals section with historic and forecast data ... more. Complete report on the Cell ... 15 companies and supported with 261 tables and ... . The Global Cell Culture Media ...
(Date:6/22/2016)... Research and Markets has announced the addition of the ... The global biomarkers market has ... The market is expected to grow at a five-year compound annual ... $50.6 billion in 2015 to $96.6 billion in 2020. ... to 2020) are discussed. As well, new products approved in 2013 ...
(Date:6/22/2016)... 2016   StockNewsNow.com , The Official MicroCap News ... Nader Pourhassan , President & CEO of CytoDyn ... clinical development and potential commercialization of humanized monoclonal antibodies ... to the company,s website (see here: www.CytoDyn.com ). ... th , 2016, at the LD Micro Invitational in ...
(Date:6/22/2016)... --  ViaCyte, Inc. , a privately-held regenerative medicine company ... for the treatment of diabetes in clinical-stage development, today ... 2016, the Global Stem Cell Event, is taking place ... Francisco.    ... Focus Session: Tools for Basic and Applied Stem Cell ...
Breaking Biology Technology:
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
Breaking Biology News(10 mins):